Primary study · included by 1 review

Evaluation of clinical efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in desquamative gingivitis, manifestation of oral lichen planus.

Kavlakova 2022 · Kavlakova Lilia · Folia medica · 2022

Included by

Evaluating calcineurin inhibitors as alternatives to steroids in treating Oral Lichen Planus: a systematic review and meta-analysis.

Non-Cochrane · intervention · 2026 · cited as Kavlakova 2022 · Reference list, ref 43 (included RCT); Supplementary Table S1

Outcome this study informs	Pooled effect	Evidence	Certainty
Pain severity (VAS 0-10) Topical steroids (clobetasol, betamethasone, triamcinolone) vs Other treatments in the network · 4 weeks	SUCRA 61	5 studies · 275 participants	GRADE not reported
Pain severity (VAS 0-10) Topical calcineurin inhibitors (tacrolimus, pimecrolimus, cyclosporin) vs Topical steroids (clobetasol, betamethasone, triamcinolone) · 4 weeks (follow-up weeks 3-4)	MD -0.06 [-0.55, 0.44]	5 studies · 276 participants	Moderate
Pain severity (VAS 0-10) Placebo vs Other treatments in the network · 4 weeks	SUCRA 13.74	5 studies · 275 participants	GRADE not reported
Pain severity (VAS 0-10) Topical calcineurin inhibitors (tacrolimus, pimecrolimus, cyclosporin) vs Topical steroids (clobetasol, betamethasone, triamcinolone) · 4 weeks	MD -0.11 [-0.97, 0.62]	5 studies · 275 participants	GRADE not reported
Pain severity (VAS 0-10) Topical calcineurin inhibitors (tacrolimus, pimecrolimus, cyclosporin) vs Other treatments in the network · 4 weeks	SUCRA 75.27	5 studies · 275 participants	GRADE not reported

1 including review in total.